Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic

On December 22, 2021, the United States FDA approved inclisiran, an siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and statin therapy for low-density lipoprotein cholesterol (LDL-C) reduction in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD).1 Inclisiran has demonstrated ∼50% time-averaged reduction in LDL-C and offers potential in promoting patient adherence as a twice-yearly long-acting injectable.

Source: Journal of Clinical Lipidology - October 31, 2022 Category: Lipidology Authors: Tommy T. Chiou, Kimberly Tomasi, Pam R. Taub, Michael J. Wilkinson Tags: Brief Communication Source Type: research